CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents Corp has demonstrated promising financial indicators, with fourth-quarter gross margins anticipated to range between 73% and 75%, contributing to a full-year gross margin improvement to approximately 72%. Full-year revenue increased by 4% to $37.1 million, while management forecasts sustained gross margins of 71% to 74% for FY26, supported by lower operating costs and a path to operating cash flow breakeven in the second half of 2026. Additionally, the company has strengthened its liquidity through credit agreement amendments and focuses on operational efficiencies, particularly in the German market, which is expected to underpin ongoing profitability improvements.

CytoSorbents Corp reported a decline in direct sales in Germany by 10%, totaling $11.8 million, which signals potential issues in their primary market. Additionally, the company's fourth quarter revenue remained flat year over year at approximately $9.2 million, and full-year revenue growth was limited to about 4% compared to the previous year, indicating stagnation in overall sales performance. Furthermore, management's decision to slow down the regulatory submission process for the DrugSorb-ATR device raises concerns about future revenue prospects and operational alignment with FDA expectations.